EUVIMEDEUVIMED entdecken
Crossref

Financial toxicity in early‐phase cancer clinical trial participants

Sienna M Durbin iD, Debra Lundquist iD, Andrea Pelletier, Laura A Petrillo iD, Viola Bame, Victoria Turbini, Hope Heldreth, Kaitlyn Lynch, Mary Boulanger iD, Anh Lam iD, Casandra McIntyre, Betty R Ferrell und 3 weitere

Cancer · 2025-01 · 131 (1)

DOI: 10.1002/cncr.35586 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 10.10.2024. Verfasst von Sienna M Durbin und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital & Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Quality of Life, Neoplasms, Patient Reported Outcome Measures. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Massachusetts General Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Little is known about financial toxicity in early‐phase clinical trial (EP‐CT) participants. This study sought to describe financial toxicity in EP‐CT participants and assess associations with patient characteristics and patient‐reported outcomes (PROs).

Methods

Prospectively enrolled EP‐CT participants from were followed from April 2021 through January 2023. Participants completed the Comprehensive Score for Financial Toxicity (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeNeoplasmsPatient Reported Outcome MeasuresHumansFemaleMaleMiddle AgedAgedAdultAged, 80 and overProspective StudiesClinical Trials as TopicCost of IllnessFinancial Stress

Stichwörter der Autor:innen

clinical trialsearly‐phase clinical trialsfinancial toxicity

Autor:innen und Institutionen

  • Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital & Harvard Medical School, Boston, Massachusetts, USA.
  • Cancer Center Protocol Office, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Biostatistician, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Division of Palliative Care and Geriatric Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • University of Oklahoma Stephenson Cancer Center, Oklahoma City, Oklahoma, USA.

ORCID-Profile: Sienna M Durbin, Debra Lundquist, Laura A Petrillo, Mary Boulanger, Anh Lam, Dejan Juric, Ryan D Nipp

Förderung

  • Massachusetts General Hospital

Zitieren

APA

Durbin, S. M., Lundquist, D., Pelletier, A., Petrillo, L. A., Bame, V., Turbini, V., Heldreth, H., Lynch, K., Boulanger, M., Lam, A., McIntyre, C., Ferrell, B. R., Jimenez, R., Juric, D., & Nipp, R. D. (2025). Financial toxicity in early‐phase cancer clinical trial participants. Cancer, 131(1). https://doi.org/10.1002/cncr.35586

Vancouver

Durbin SM, Lundquist D, Pelletier A, Petrillo LA, Bame V, Turbini V, et al. Financial toxicity in early‐phase cancer clinical trial participants. Cancer. 2025;131(1). doi:10.1002/cncr.35586

BibTeX
@article{Durbin2025,
  author = {Durbin, Sienna M and Lundquist, Debra and Pelletier, Andrea and Petrillo, Laura A and Bame, Viola and Turbini, Victoria and Heldreth, Hope and Lynch, Kaitlyn and Boulanger, Mary and Lam, Anh and McIntyre, Casandra and Ferrell, Betty R and Jimenez, Rachel and Juric, Dejan and Nipp, Ryan D},
  title = {Financial toxicity in early‐phase cancer clinical trial participants},
  journal = {Cancer},
  year = {2025},
  volume = {131},
  number = {1},
  doi = {10.1002/cncr.35586}
}
Kostenlos starten →